FNCH - Finch Therapeutics Group, Inc. Stock Price, Fair Value and News

$11.00+0.60 (+5.77%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FNCH Price Action

Last 7 days

-8.3%

Last 30 days

-3.9%

Last 90 days

-3.5%

Trailing 12 Months

251.4%

FNCH RSI Chart

FNCH Valuation

Market Cap

17.7M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

188.19

EV/EBITDA

-0.12

Price/Free Cashflow

-0.98

FNCH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FNCH Fundamentals

FNCH Revenue

Revenue (TTM)

107.0K

Rev. Growth (Yr)

-45.95%

Rev. Growth (Qtr)

-26.66%

FNCH Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

30.45%

Earnings Growth (Qtr)

-24.72%

FNCH Profitability

EBT Margin

-13240.19%

Return on Equity

-99.63%

Return on Assets

-31.08%

Free Cashflow Yield

-102.14%

FNCH Investor Care

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

-8.65

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	521.0K	580.0K	927.0K	107.0K
2022	14.1M	9.7M	5.3M	861.0K
2021	9.5M	10.0M	19.5M	18.5M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

WEBSITE	finchtherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	18

Finch Therapeutics Group, Inc. Frequently Asked Questions

What is the ticker symbol for Finch Therapeutics Group, Inc.? What does FNCH stand for in stocks?

FNCH is the stock ticker symbol of Finch Therapeutics Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Finch Therapeutics Group, Inc. (FNCH)?

As of Fri Dec 20 2024, market cap of Finch Therapeutics Group, Inc. is 17.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FNCH stock?

You can check FNCH's fair value in chart for subscribers.

Is Finch Therapeutics Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether FNCH is over valued or under valued. Whether Finch Therapeutics Group, Inc. is cheap or expensive depends on the assumptions which impact Finch Therapeutics Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FNCH.

What is Finch Therapeutics Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, FNCH's PE ratio (Price to Earnings) is -1.25 and Price to Sales (PS) ratio is 188.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FNCH PE ratio will change depending on the future growth rate expectations of investors.